Domestic institutional investors (DIIs) maintained their strong buying spree in Indian equities through June 2025, with net inflows reaching Rs. 69,176.47 crore as of June 27. This marks the second-highest monthly inflow by DIIs so far this year, reflecting continued confidence in the market.
That said, on 27th June, DIIs turned net sellers, pulling out around Rs. 588.93 crore, based on provisional data from the exchanges. However, this was likely a brief pause after a month of sustained buying.
Among the many stocks that saw increased DII interest in June 2025, here are two companies where institutional investors increased their stake:
UGRO Capital Limited
With a market cap of Rs. 2,042.6 crores, the stock moved up by nearly 1 percent on BSE, rising to Rs. 176.15 on Friday. Domestic institutional investors (DIIs) holdings have grown to 2.65 percent in June 2025, up by 0.8 percent from 1.85 percent in March 2025 and by 0.1 percent from 2.55 percent in June 2024.
In Q4 FY25, Ugro Capital has witnessed a growth of nearly 25 percent YoY in revenue from operations to Rs. 403 crores, accompanied by a net profit growth of around 24 percent YoY to Rs. 41 crores.
UGRO Capital Limited, a non-deposit taking Non-Banking Financial Company (NBFC-ND), is engaged in the business of lending and primarily deals in financing the MSME sector with a focus on healthcare, education, chemicals, food processing/FMCG, hospitality, electrical equipment & components, auto components, micro enterprises and light engineering.
Biocon Limited
With a market cap of Rs. 50,510.5 crores, the stock moved up by nearly 1.3 percent on BSE, rising to Rs. 379.3 on Friday. DII holdings have grown to 21.45 percent in June 2025, up by 5.72 percent from 15.73 percent in March 2025 and by 7.16 percent from 14.29 percent in June 2024.
In Q4 FY25, Biocon has witnessed a growth of nearly 13 percent YoY in revenue from operations to Rs. 4,417 crores, accompanied by a net profit growth of around 106 percent YoY to Rs. 459 crores.
Biocon Limited is engaged in the business of manufacturing and offering biotechnology products and research services. It is an innovation-led global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer, and autoimmune diseases.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
